Calcium folinate pentahydrate intended for immediate-release oral tablets is transferred from quarantine only after the lot has been verified against particle-size and water-content parameters defined in the site master formula. The release protocol includes laser-diffraction measurement using a Malvern Mastersizer 3000 with dry dispersion at 1 bar; acceptance is normally set at D90 ≤ 250 µm and D50 75–150 µm. A direct compression route is selected for 5 mg, 10 mg, 15 mg, and 25 mg strengths because the pentahydrate form remains processable when ambient relative humidity is controlled below 40%. In a representative 15 mg tablet batch, the API mass fraction is 15.0% w/w; microcrystalline cellulose PH-102 constitutes 78.5%, croscarmellose sodium 5.0%, colloidal silicon dioxide 1.0%, and magnesium stearate 0.5%. The API is first preblended with colloidal silicon dioxide for 10 min in a 600 L bin blender at 12 rpm, screened through a 0.5 mm sieve, and then combined with the remaining excipients. Final lubrication is limited to 5 min; extended mixing beyond 10 min is prohibited because magnesium stearate coating increases disintegration time and depresses the dissolution plateau at 30 min. Tablets are compressed on a Korsch XL 400 rotary press equipped with 10 mm round flat-faced bevel-edge tooling at a compression force of 8 kN to 14 kN, a press speed of 40–70 rpm, and a target hardness of 70–90 N. In-process controls include tablet mass variation per USP <905>, friability per USP <1216> with a limit of ≤1.0%, and disintegration per USP <701> in 37°C water with a limit of ≤15 min. Finished-product dissolution is performed per USP <711> Apparatus II in 900 mL purified water at 50 rpm; the acceptance criterion is Q = 80% in 45 min. Elemental impurities are controlled under ICH Q3D Option 1, with oral permissible daily exposures of 5 µg/day for lead and 2 µg/day for cadmium. The terminal product is an uncoated or film-coated tablet for oral administration in methotrexate rescue protocols and as a component of fluorouracil-containing regimens.

What Changes When Wet Granulation Precedes High-Dose Capsule Filling?

When the dose per capsule reaches 50 mg or the API fraction exceeds 30% w/w, direct compression becomes difficult because the flowable excipient fraction is too small to compensate for the cohesive behavior of calcium folinate pentahydrate. The process is therefore shifted to high-shear wet granulation in a Fielder PMA 100 or equivalent 100 L bowl. A binder solution of povidone K30 at 5.0% w/w in purified water is added at 18–22% of dry blend mass over 5–7 min; impeller speed is held at 250–350 rpm and chopper speed at 1500 rpm during the wet massing phase. The granule endpoint is confirmed by a torque increase of 20–30% from the dry blend baseline and by the formation of coarse agglomerates. The wet mass is passed through a 1.5 mm screen and dried in a Glatt GPCG 120 fluid-bed dryer with inlet air at 55°C maximum; product temperature is kept at 32–38°C to protect the pentahydrate water of crystallization from surface stripping. Drying continues until granule moisture content reaches 2.0–3.5% by loss on drying at 105°C for 15 min. Dried granules are dry-milled through a 0.8 mm screen and blended with croscarmellose sodium 2.0% w/w and magnesium stearate 0.5% w/w for 3 min. Capsule filling is performed on an MG2 Planeta or Bosch GKF 2500 with size 0 hard gelatin capsules; fill weight is adjusted to deliver 50 mg of calcium folinate pentahydrate per capsule with a target weight range of ±5%. Dissolution is tested per USP <711> Apparatus I in 900 mL water at 100 rpm; the acceptance criterion is Q = 75% in 60 min. The terminal product is an immediate-release capsule for oral administration in patients requiring high-dose folinate rescue or combination chemotherapy.

Lyophilized Injection Manufacturing and Subvisible Particulate Control

Injectable presentations of calcium folinate pentahydrate are manufactured as either ready-to-use solution at 10 mg/mL or as lyophilized powder for reconstitution. The solution formulation contains calcium folinate pentahydrate equivalent to leucovorin calcium 10 mg/mL and sodium chloride 8.5 mg/mL; pH is adjusted to 6.5–8.5 with hydrochloric acid or sodium hydroxide. The compounded solution is passed through a 0.22 µm PVDF membrane filter and filled into Type I borosilicate glass vials conforming to ISO 8362-1. The filling line operates under Grade A laminar airflow within a Grade B background as defined by EU GMP Annex 1. Lyophilized vials are loaded onto stainless steel trays at fill volumes of 5 mL, 10 mL, or 35 mL; the lyophilization cycle is developed by freeze-drying microscopy and differential scanning calorimetry to avoid collapse. Primary drying is conducted with a shelf temperature of −20°C to −10°C and a chamber pressure of 100–200 µbar; secondary drying is ramped to 25°C to reduce residual moisture to ≤2.0%. Finished vials are tested for bacterial endotoxin per USP <85>, sterility per USP <71>, particulate matter per USP <788>, and sub-visible particle counts per Ph. Eur. 2.9.19. The acceptance for sub-visible particles is ≤6,000 particles per container at ≥10 µm and ≤600 particles per container at ≥25 µm for parenteral preparations. The terminal product is an injectable solution or lyophilized powder for intravenous or intramuscular administration after reconstitution; it is used in methotrexate rescue and as a modulator of fluorouracil.

If the API Is Compounded into Oral Granules for Unit-Dose Sachets

Calcium folinate pentahydrate granules are produced as a single-dose powder intended for reconstitution or direct oral administration in populations at risk of swallowing difficulties. The API is blended with mannitol Pearlitol 200SD, maize starch, and citric acid anhydrous; citric acid is fixed at 0.5% w/w to provide a weak acidic environment that stabilizes the hydrate in a sachet exposed to intermittent humidity. A typical granule formulation contains 10.0% w/w API, 84.5% mannitol, 5.0% maize starch, and 0.5% citric acid. Granulation is carried out in a fluid-bed unit using an aqueous solution of hypromellose 3 cps as binder at 4.0% w/w concentration; spray rate is maintained at 25–35 g/min for a 10 kg batch. Inlet air temperature is set at 50°C maximum, product temperature at 30–35°C, and drying is stopped at loss on drying 1.5–2.5%. The dried granules are screened through a 1.0 mm sieve and filled into four-side-sealed aluminum foil sachets with a moisture vapor transmission rate below 0.5 g/m²/day at 38°C and 90% RH, tested per ASTM F1249. Fill weight is adjusted to deliver 10 mg or 15 mg calcium folinate pentahydrate per sachet; content uniformity follows USP <905>. Dissolution is performed per USP <711> Apparatus II at 50 rpm in 500 mL water, with Q = 80% at 30 min. The terminal product is a single-dose oral granule with a labeled stability profile under refrigeration at 2–8°C; reconstitution with 20 mL water yields a suspension for immediate use.

In hospital pharmacy practice, calcium folinate pentahydrate injection is commonly diluted for continuous or bolus intravenous administration in methotrexate rescue and fluorouracil modulation. The admixture is prepared in a barrier isolator or biological safety cabinet that maintains ISO Class 5 air quality, as required by USP <797>. The single-dose vial is not reused once the closure has been punctured; because the injection contains no antimicrobial preservative, open-vial storage beyond 4 h at room temperature is considered unacceptable in many institutional standard operating procedures. Dilution is typically made with 0.9% sodium chloride injection or 5% dextrose injection to a final leucovorin concentration of 0.5 mg/mL to 2.0 mg/mL. The final admixture is protected from light during administration. Calcium folinate is not mixed with fluorouracil in the same infusion container; separate lines or sequential infusion is required because the divalent calcium ion and the pH range of the admixture create conditions that are outside the validated compatibility envelope for fluorouracil. Published co-infusion stability data for this specific combination is limited, so the admixture is assigned a conservative beyond-use date under USP <797> risk categories. Filtration is not routinely required if the admixture is prepared from a licensed injection and administered by intravenous infusion set with an in-line 0.2 µm filter; this filter type is used to remove particulate matter without reducing potency. The terminal patient-specific product is an intravenous admixture labeled with patient identity, dose, date, time, and infusion rate, and it is administered under oncologist supervision.

Aqueous Film Coating of Immediate-Release Calcium Folinate Tablets

Tablets containing calcium folinate pentahydrate are coated with a thin aqueous film to improve swallowability and to provide a physical barrier against ambient moisture. The coating process is performed in a perforated pan coater, such as a Glatt GC 750 or similar 750 L pan, charged with core tablets at 75–85% of pan volume. The coating dispersion contains hypromellose 2910, talc, titanium dioxide, and polyethylene glycol in purified water at 12% w/w total solids; the weight gain target is 2.5–3.5% of the core tablet mass. Pan speed is set at 6–10 rpm, inlet air temperature at 55–65°C, and exhaust temperature at 35–45°C; spray rate is adjusted to 40–60 g/min per nozzle so that the tablet surface remains dry to the touch and no overwetting occurs. Overwetting is a critical failure mode because calcium folinate pentahydrate tablets soften when surface moisture exceeds 4%; this leads to edge chipping and dissolution failure. After coating, the tablets are dried in the same pan at 40°C for 5–10 min and then discharged onto a vibratory screen to remove coating agglomerates. The coated tablets are tested for disintegration per USP <701> with a limit of ≤15 min in 37°C water, dissolution per USP <711> Apparatus II at 50 rpm in 900 mL water with Q = 80% in 45 min, and moisture content by Karl Fischer titration with a limit of ≤4.0%. The terminal product is a film-coated immediate-release tablet labeled for oral administration.